HALOZYME THERAPEUTICS, INC. - Common Stock (HALO)

Historical Holders from Q1 2014 to Q3 2025

Symbol
HALO on Nasdaq
CUSIP
40637H109
Type / Class
Equity / Common Stock
Shares outstanding
124M
All holders as of September 30, 2025
Q3 2025
Total 13F shares, excl. options
119M
Holdings value
$8.74B
% of all portfolios
0.009%
Grand Portfolio weight change
+0%
Number of holders
590
Number of buys
290
Number of sells
-283
Average Value change %
0%
Average buys %
+0.001%
Average sells %
-0.002%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of HALOZYME THERAPEUTICS, INC. - Common Stock (HALO)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 10.2% -22.3% $656M -$184M 12.6M -21.9% BlackRock, Inc. Jun 30, 2025
STATE STREET CORP 4.9% $359M 6.05M STATE STREET CORPORATION Mar 31, 2025

Institutional Holders of HALOZYME THERAPEUTICS, INC. - Common Stock (HALO)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 119M $8.74B +$221M $73.34 590
2025 Q2 116M $6.05B -$203M $52.02 540
2025 Q1 120M $7.68B -$91.6M $63.81 541
2024 Q4 122M $5.86B -$141M $47.81 497
2024 Q3 124M $7.1B +$131M $57.24 501
2024 Q2 122M $6.4B +$5.31M $52.36 450
2024 Q1 123M $4.98B -$61.6M $40.68 408
2023 Q4 124M $4.6B +$92.8M $36.96 408
2023 Q3 121M $4.64B -$48M $38.20 387
2023 Q2 122M $4.42B -$50.5M $36.07 367
2023 Q1 124M $4.72B -$280M $38.19 381
2022 Q4 129M $7.31B -$116M $56.90 414
2022 Q3 131M $5.18B +$146M $39.54 344
2022 Q2 127M $5.59B +$58.6M $44.00 358
2022 Q1 126M $5.03B -$49.6M $39.88 299
2021 Q4 128M $5.13B -$91.3M $40.21 313
2021 Q3 129M $5.23B +$23.5M $40.68 315
2021 Q2 129M $5.84B -$91.2M $45.41 309
2021 Q1 131M $5.47B -$142M $41.69 327
2020 Q4 136M $5.82B +$128M $42.71 335
2020 Q3 134M $3.52B -$34.2M $26.28 265
2020 Q2 135M $3.62B +$159M $26.81 257
2020 Q1 131M $2.35B +$56.3M $17.99 207
2019 Q4 127M $2.26B +$7.24M $17.73 220
2019 Q3 126M $1.96B +$54.9M $15.51 207
2019 Q2 123M $2.1B +$208M $17.18 200
2019 Q1 121M $1.95B +$3.48M $16.10 198
2018 Q4 120M $1.76B -$41.6M $14.63 184
2018 Q3 123M $2.23B +$6.4M $18.17 192
2018 Q2 123M $2.07B -$21.2M $16.87 193
2018 Q1 124M $2.42B +$15.4M $19.59 208
2017 Q4 122M $2.48B +$20.9M $20.26 199
2017 Q3 121M $2.11B -$3.85M $17.37 169
2017 Q2 122M $1.56B +$88M $12.82 169
2017 Q1 115M $1.49B +$199M $12.96 156
2016 Q4 111M $1.09B +$44.5M $9.88 171
2016 Q3 106M $1.28B +$17.3M $12.08 161
2016 Q2 105M $907M +$19.2M $8.63 159
2016 Q1 101M $962M +$1.18M $9.47 159
2015 Q4 98.8M $1.71B +$8.22M $17.33 164
2015 Q3 98.2M $1.32B -$2.11M $13.43 174
2015 Q2 95.9M $2.17B +$80.1M $22.58 159
2015 Q1 92.7M $1.32B +$53.3M $14.28 137
2014 Q4 91.2M $880M +$20.1M $9.65 130
2014 Q3 89M $810M +$28.5M $9.10 118
2014 Q2 85.7M $846M -$18.6M $9.88 129
2014 Q1 85.9M $1.09B +$80.4M $12.70 129